#ACTRIMS2021

#ACTRIMS2021 – Long-term Uplizna Reduces NMOSD Attacks, Trial Data Show

Long-term treatment with Uplizna (inebilizumab-cdon) is safe and sustainably reduces the frequency of attacks in adults with neuromyelitis optica spectrum disorder (NMOSD), according to four-year data from the N-MOmentum Phase 2/3 clinical trial. Notably, these benefits also were observed among patients who previously received rituximab, an immunosuppressive therapy often…

#ACTRIMS2021 – Expert Lectures About Available NMOSD Treatments

An improved understanding of the biological processes that drive neuromyelitis optica spectrum disorder (NMOSD) has led to treatment advancements in recent years. In a presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2021, Sean Pittock, MD, director of the Mayo Clinic’s Center for…

#ACTRIMS2021 – Complex Ways That AQP4-IgG Drives NMOSD Detailed

In most people with neuromyelitis optica spectrum disorder (NMOSD), autoantibodies against aquaporin-4 (AQP4) coordinate a complex series of immune activities that drive the disease. Better understanding of these disease-causing mechanisms may help in efforts to find new treatments for NMOSD patients. These mechanisms were explained in the lecture, “…